On November 14, 2017, Theradiag, a French company specializing in in vitro diagnostics, announced that it had entered into a partnership agreement with Biogen to provide LISA TRACKER kits for monitoring Flixabi®, Biogen’s infliximab biosimilar that is marketed in Europe. Theradiag’s LISA TRACKER kits allow clinicians to monitor trough plasma levels of circulating TNFα, prescribed anti-TNF-α, and the presence of anti-drug antibodies in order to optimize patient treatment.
Through its partner Miraca Life Sciences, Theradiag markets LISA TRACKER kits in the United States under the name InformTxTM for Remicade® (infliximab), Humira® (adalimumab), Entyvio® (vedolizumab), Inflectra® (infliximab‑dybb), Cimzia® (certolizumab pegol), Stelara® (ustekinumab) and Simponi® (golimumab). Theradiag recently announced that it will begin marketing an eighth monitoring test for Renflexis® (infliximab-abda) in the US once validation is complete.
